Your Article Summary
See Latest ArticlesCell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
Cell Therapeutics, 06/25/09
Cell Therapeutics, Inc. announced that it has completed the submission of the New Drug Application to the U.S. Food and Drug Administration for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma. CTI requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Two Delivery Systems Win Baldrige Award
HealthDataManagement, 12/17/09
Advisory Committee briefing materials for CRESTOR sNDA available on US FDA web site
AstraZeneca, 12/15/09
Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09